See Scientist To Watch Phil Baran describe the artistry of his research in drug discovery.
By Abby Olena | February 1, 2014
Read the full story.
Sign In with your LabX Media Group Passport to leave a comment
Not a member? Register Now!
By Jef Akst
Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.
By Kerry Grens
The personal genomics firm announces plans to make medicines.
By Bob Grant
The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.
View the April 2015 contents.
© 1986-2015 The Scientist